{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:56:07Z","timestamp":1791834967594,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[1997,10,1]],"date-time":"1997-10-01T00:00:00Z","timestamp":875664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[1997,10]]},"DOI":"10.1007\/bf03348017","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T13:31:27Z","timestamp":1396618287000},"page":"547-551","source":"Crossref","is-referenced-by-count":61,"title":["Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy"],"prefix":"10.1007","volume":"20","author":[{"given":"E.","family":"Ciccarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Razzore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cammarota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Camanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Camanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,2]]},"reference":[{"key":"BF03348017_CR1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.1987.tb03072.x","volume":"23","author":"AE Pontiroli","year":"1987","unstructured":"Pontiroli A.E., Viberti G.C., Mangili R., Cammelli L., Dubini A. Selective and extremely long inhibition of PRL release in man by 1-ethyl 3 (3\u2032 Dimethylamino propyl) urea-diphosphate (FCE 21336). Br. J. Clin. Pharmacol. 23: 433, 1987.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BF03348017_CR2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1210\/jcem-65-3-541","volume":"65","author":"GB Melis","year":"1987","unstructured":"Melis G.B., Gambacciani M., Paoletti A.M., Beneventi F., Mais V., Baroldi P., Fioretti P. Dose-related prolactin inhibitory effects of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women. J. Clin. Endocrinol. Metab. 65: 541, 1987.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03348017_CR3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-63-4-941","volume":"63","author":"C Ferrari","year":"1986","unstructured":"Ferrari C., Barbieri C., Caldara R., Mucci M., Codecasa F., Paracchi A., Romano C., Boghen M., Dubini A. Long lasting PRL-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 63: 941, 1986.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03348017_CR4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1210\/jcem-69-4-725","volume":"69","author":"E Ciccarelli","year":"1989","unstructured":"Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 69: 725, 1989.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03348017_CR5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1210\/jcem-68-6-1201","volume":"68","author":"C Ferrari","year":"1989","unstructured":"Ferrari C., Mattei A., Melis G.B., Paracchi A., Muratori M., Faglia G., Sghedoni D., Crosignani P.G. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J. Clin. Endocrinol. Metab. 68: 1201, 1989.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03348017_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","volume":"39","author":"J Webster","year":"1993","unstructured":"Webster J., Piscitelli G., Polli A., Dalberto A., Farsetti L., Ferrari C., Fioretti P., Giordano G., L\u2019Hermite M., Ciccarelli E., Crosignani P.G., De Cecco L., Fadini R., Faglia G., Flamigni C., Tamburrano G., Ismail I., Scanion M.F. (European multicentre CAB study group). The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin. Endocrinol. 39: 323, 1993.","journal-title":"Clin. Endocrinol."},{"key":"BF03348017_CR7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/acta.0.1260489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C., Paracchi A., Mattei M., de Vincentiis S., D\u2019Alberton A., Crosignani P.G. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 126: 489, 1992.","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BF03348017_CR8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","volume":"10","author":"E Robert","year":"1996","unstructured":"Robert E., Musatti L., Piscitelli G., Ferrari C. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 10: 333, 1996.","journal-title":"Reprod. Toxicol."},{"key":"BF03348017_CR9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O. and the bromocriptine study group. Bromocriptine as primary therapy for PRL-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03348017_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00347554","volume":"23","author":"G Scotti","year":"1982","unstructured":"Scotti G., Scialfa G., Pieralli S., Chiodini P.G., Spelta B., Dallabonzana D. Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment. Neuroradiology 23: 123, 1982.","journal-title":"Neuroradiology"},{"key":"BF03348017_CR11","first-page":"484","volume":"76","author":"E Ciccarelli","year":"1993","unstructured":"Ciccarelli E., Miola C., Grottoli S., Avataneo T., Lancranjan J., Camanni F. Long term therapy of patients with macroprolactinomas using repeatable, injectable bromocriptine. J. Clin. Endocrinol. Metab. 76: 484, 1993.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 1","key":"BF03348017_CR12","first-page":"6","volume":"6","author":"E Salle Di","year":"1982","unstructured":"Di Salle E., Ornati G., Briatico G. FCE 21336, a new ergoline derivative with long-acting lowering effect on prolactin secretion in rats. (Abstract). J. Endocrinol. Invest. 6(Suppl 1): 6, 1982.","journal-title":"J. Endocrinol. Invest."},{"key":"BF03348017_CR13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0014-2999(90)90367-F","volume":"187","author":"M Strolin Benedetti","year":"1990","unstructured":"Strolin Benedetti M., Dster P., Barone D., Efthymiopoulos C., Peretti G., Roncucci R. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur. J. Pharmacol. 187: 399, 1990.","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl 1","key":"BF03348017_CR14","first-page":"32","volume":"7","author":"E Salle Di","year":"1984","unstructured":"Di Salle E., Ornati G., Giudici D. A comparison of the in vivo and in vitro duration of prolactin lowering effect in rats of FCE 21336, pergolide and bromocriptine (Abstract). J. Endocrinol. Invest. 7(Suppl 1): 32, 1984.","journal-title":"J. Endocrinol. Invest."},{"key":"BF03348017_CR15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198505233122106","volume":"312","author":"ME Molitch","year":"1985","unstructured":"Molitch M.E. Pregnancy and hyperprolactinemic women. New Engl. J. Med. 312: 1364, 1985.","journal-title":"New Engl. J. Med."},{"key":"BF03348017_CR16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/01443619109013511","volume":"11","author":"L Falsetti","year":"1991","unstructured":"Falsetti L., Zanagnolo V., Galbignani E. Cabergoline treatment in hyperprolactinemic women. J. Obstet. Gynaecol. 11: 68, 1991.","journal-title":"J. Obstet. Gynaecol."},{"key":"BF03348017_CR17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J., Piscitelli G., Polli A., Ferrari C., Ismail I., Scanion M.F. for the cabergoline comparative study group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New Engl. J. Med. 331: 904, 1994.","journal-title":"New Engl. J. Med."},{"key":"BF03348017_CR18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0028-2243(80)90078-7","volume":"10","author":"L Belforte","year":"1980","unstructured":"Belforte L., Bruno M., Campagnoli C., Fessia L., Massara F., Molinatti G.M. Hormone patterns during bromocriptine-induced pregnancy in hyperprolactinemic patients. Eur. J. Obstet. Gynecol. Reprod. Biol. 10: 309, 1980.","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03348017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03348017\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03348017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:05:32Z","timestamp":1648757132000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03348017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,10]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1997,10]]}},"alternative-id":["BF03348017"],"URL":"https:\/\/doi.org\/10.1007\/bf03348017","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,10]]}}}